Treatment of stage I seminoma: Is it time to change your practice?

Journal of Hematology and Oncology

Volumn 1, Issue 1, 2008, Pages

  Feldman, Darren R ^a   Bosl, George J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN;

ADJUVANT THERAPY; ARTICLE; CANCER STAGING; HUMAN; MALE; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEMINOMA; TESTIS TUMOR;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MALE; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 68549128953     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-1-22     Document Type: Review

References (16)

1. Oliver RT, Mead GM, Fogarty PJ, Stenning SP, MRC TE19 and EORTC 30982 trial collaborators: Radiotherapy versus carboplatin for stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214) [Abstract]. J Clin Oncol 2008, 26:1.
2. Oliver RT, Mason MD, Mead GM, Maase H von der, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP: Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005, 366:293-300. (Pubitemid 41019418)
3. Cooper DE, L'Esperance JO, Christman MS, Auge BK: Testis cancer: a 20-year epidemiological review of the experience at a regional military medical facility. J Urol 2008, 180:577-581. discussion 581-572.
4. Brenner DJ, Hall EJ: Computed tomography - an increasing source of radiation exposure. N Engl J Med 2007, 357:2277-2284. (Pubitemid 350190758)
5. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice JD Jr, Dores GM, Gilbert ES: Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005, 97:1354-1365. (Pubitemid 41487803)
6. Belt-Dusebout AW van den, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BM, van Leeuwen FE: Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007, 25:4370-4378. (Pubitemid 350013842)
7. Belt-Dusebout AW van den, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PT, Schimmel EC, Aleman BM, van Leeuwen FE: Long-term risk of cardiovascular disease in 5year survivors of testicular cancer. J Clin Oncol 2006, 24:467-475. (Pubitemid 46630466)
8. Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T: The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 2008, 19:443-447. (Pubitemid 351336907)
9. Alomary I, Samant R, Gallant V: Treatment of stage I seminoma: a 15-year review. Urol Oncol 2006, 24:180-183.
10. Bosl GJ, Vogelzang NJ, Goldman A, Fraley EE, Lange PH, Levitt SH, Kennedy BJ: Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet 1981, 2:970-973.
11. Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, Geller NL, Fair WR, Herr H, Sogani P, et al.: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993, 11:598-606. (Pubitemid 23105666)
12. Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997, 15:1844-1852. (Pubitemid 27209513)
13. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, Maase H von der: Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002, 20:4448-4452. (Pubitemid 35334756)
14. Valdevenito JP, Gallegos I, Fernandez C, Acevedo C, Palma R: Correlation between primary tumor pathologic features and presence of clinical metastasis at diagnosis of testicular seminoma. Urology 2007, 70:777-780. (Pubitemid 350030216)
15. Aparicio J, Garcia del Muro X, Maroto P, Paz-Ares L, Alba E, Saenz A, Terrasa J, Barnadas A, Almenar D, Arranz JA, Sanchez M, Fernandez A, Sastre J, Carles J, Dorca J, Guma J, Yuste AL, Germa JR: Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 2003, 14:867-872. (Pubitemid 36827202)
16. Aparicio J, Germa JR, Garcia del Muro X, Maroto P, Arranz JA, Saenz A, Barnadas A, Dorca J, Guma J, Olmos D, Bastus R, Carles J, Almenar D, Sanchez M, Paz-Ares L, Satrustegui JJ, Mellado B, Balil A, LopezBrea M, Sanchez A: Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 2005, 23:8717-8723. (Pubitemid 46211516)